Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Rationale for Pembrolizumab Plus mFOLFOX6 in Advanced CRC

November 15th 2018

Matthew Farren, PhD, post-doctoral fellow, Winship Cancer Institute, Emory University, discusses the rationale behind the combination of pembrolizumab (Keytruda) and modified leucovorin/5-fluorouracil/oxaliplatin (mFOLFOX6) in patients with advanced colorectal cancer.

Dr. O'Connor on Real-World Results With Regorafenib in mCRC

November 13th 2018

Juan Manuel O’Connor, MD, head, Department Gastrointestinal Oncology, Department of Clinical Oncology, Institute Alexander Fleming, Buenos Aires, discusses real-world results with regorafenib (Stivarga) in the treatment of patients with metastatic colorectal cancer (mCRC).

Dr. Bekaii-Saab on the Impact of Next-Generation Sequencing in mCRC

November 9th 2018

Tanios Bekaii-Saab, MD, medical oncologist, Mayo Clinic, discusses the utility of next-generation sequencing in metastatic colorectal cancer (mCRC).

Obesity Impact Draws Increased Scrutiny in GI Malignancies

November 6th 2018

Obesity is associated with an increased risk of early-onset colorectal cancer among women and correlates with higher rates of cancer resections in gastrointestinal malignancies across age groups.

Dr. McCollum on the Clinical Utility of Regorafenib in mCRC

November 2nd 2018

A. David McCollum, MD, attending oncologist, Baylor University Medical Center, discusses the clinical utility of regorafenib (Stivarga) in metastatic colorectal cancer (mCRC).

Dr. Cercek on Induction Chemotherapy in Mismatch Repair Deficient Rectal Cancer

October 29th 2018

Andrea Cercek, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses induction chemotherapy in patients with mismatch repair deficient rectal cancer.

Real-World Results Reveal Regorafenib Tolerability in mCRC

October 29th 2018

Juan Manuel O’Connor, MD, discusses the final results of the CORRELATE regorafenib study in patients with metastatic colorectal cancer, emphasizing the importance of real-world data.

Dr. Lenz on the Benefit of Regorafenib in CRC

October 26th 2018

Heinz-Josef Lenz, MD, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses the benefit of regorafenib (Stivarga) in the treatment of patients with colorectal cancer (CRC).

Neoadjuvant Nivolumab Plus Ipilimumab Active in dMMR Early-Stage Colon Cancer

October 23rd 2018

First results from a study of neoadjuvant ipilimumab plus nivolumab in patients with early-stage colon cancer found a major pathologic response achieved in all 7 patients with mismatch repair deficient tumors.

Metastatic CRC: Moving Into the Future

October 22nd 2018

Precision Medicine Further Explored in Metastatic CRC

October 22nd 2018

Immunotherapy in MSS Colorectal Cancer

October 22nd 2018

Immunotherapy Regimens in dMMR/MSI-High Metastatic CRC

October 22nd 2018

Significance of MSI Status and TMB in Metastatic CRC

October 22nd 2018

Triplet Regimens in BRAF-Mutant Metastatic CRC

October 22nd 2018

Targeting BRAF in Metastatic CRC

October 22nd 2018

Tumor Sidedness in CRC: Distinguishing Factors

October 22nd 2018

Combination Strategies in Frontline Metastatic CRC

October 22nd 2018

RAS Status and Treatment Decisions in Metastatic CRC

October 22nd 2018

Recommendations for Molecular Testing in Metastatic CRC

October 22nd 2018